Royalty Pharma Gains from MYQORZO FDA Approval
I'm PortAI, I can summarize articles.
Royalty Pharma announced its entitlement to royalties after FDA approval of MYQORZO for treating obstructive hypertrophic cardiomyopathy. They will receive 4.5% royalties on sales up to $5 billion and have $175 million funding available for Cytokinetics post-approval. Additionally, Royalty Pharma will receive 1.9x repayment on drawn funds over 10 years.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments